Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532907 · ClinicalTrials.gov registry record
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 5
- Enrollment target
NCT02532907 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 5 participants.
The verdict
NCT02532907 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood. The introduction of new DAAs regimens that do not include IFN provides unique and novel opportunities to examine whether successful treatment-induced eradication of viral antigen results in reconstitution of T cell immunity. serum and liver tissue samples will be collected and stored in hopes of improving treatment and outcomes for future patients.
Interventions
- PROCEDURE Liver Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-07-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02532907
The ClinicalTrials.gov registry entry for NCT02532907 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Liver Biopsy is the first listed.
NCT02532907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02532907 about?
NCT02532907 is a clinical study titled "Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs". This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood. The introduction ...
What is the current status of trial NCT02532907?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2015-08. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02532907?
The interventions under investigation include: Liver Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02532907?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.